IP Library Patent Application 17149946
Patent Application
App. No. 17/149,946

PROBES FOR DETECTION OF HUMAN PARVOVIRUS NUCLEIC ACID

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/149,946
Abstract

Nucleic acid oligomers specific for human parvovirus genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed. Compositions for amplifying and detecting the presence of human parvovirus genotypes 1, 2 and 3 genomic DNA in human biological specimens are disclosed.

Claims (31)

1 . A detection probe oligomer comprising:

(a) a target-binding sequence that is SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:32, or SEQ ID NO:36; and

(b) a detectable label.

2 . The detection probe oligomer of claim 1 , wherein the detectable label is a chemiluminescent or fluorescent label.

3 . The detection probe oligomer of claim 1 , wherein the detectable label is a homogeneous detectable label.

4 . The detection probe oligomer of claim 3 , wherein the homogeneous detectable label is a chemiluminescent label.

5 . The detection probe oligomer of claim 4 , wherein the chemiluminescent label is an acridinium ester (AE) compound.

6 . The detection probe oligomer of claim 1 , wherein the detection probe oligomer has at least one 2′-methoxy linkage in the nucleic acid backbone.

7 . A probe reagent comprising:

(a) a detection probe oligomer comprising (i) a target-binding sequence that is SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:32, or SEQ ID NO:36, and (ii) a detectable label;

(b) succinate

(c) lithium chloride;

(d) lithium lauryl sulfate;

(e) at least one anti-coagulant selected from the group consisting of EDTA and EGTA; and

(f) ethanol.

8 . The probe reagent of claim 7 , wherein the lithium lauryl sulfate is present in the reagent at a concentration of 2% (w/v).

9 . The probe reagent of claim 7 , wherein the EDTA is present in the reagent at a concentration of 20 mM.

10 . The probe reagent of claim 7 , wherein the EGTA is present in the reagent at a concentration of 20 mM.

11 . The probe reagent of claim 7 , wherein the succinate is present in the reagent at a concentration of 100 mM.

12 . The probe reagent of claim 7 , wherein the detection probe oligomer has at least one 2′-methoxy linkage in the nucleic acid backbone.

13 . A method for the detection of an amplified human parvovirus nucleic acid comprising the steps of:

(a) providing an amplified human parvovirus nucleic acid comprising a target specific sequence that contains SEQ ID NO:88, or comprising a target specific sequence amplifiable with a primer consisting of SEQ ID NO:13 and a promoter primer consisting of SEQ ID NO:23;

(b) hybridizing the amplified human parvovirus nucleic acid with a detection probe oligomer, wherein the detection probe oligomer comprises (i) a target-binding sequence that is SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:32, or SEQ ID NO:36, and (ii) a detectable label; and

(c) detecting the label of the hybridized detection probe oligomer, thereby detecting the amplified human parvovirus nucleic acid.

14 . The method of claim 13 , wherein the detectable label is a chemiluminescent or fluorescent label.

15 . The method probe oligomer of claim 13 , wherein the detectable label is a homogeneous detectable label.

16 . The method oligomer of claim 15 , wherein the homogeneous detectable label is a chemiluminescent label.

17 . The method oligomer of claim 16 , wherein the chemiluminescent label is an acridinium ester (AE) compound.

18 . The method of claim 13 , wherein the detection probe oligomer has at least one 2′-methoxy linkage in the nucleic acid backbone.

19 . The method of claim 13 , further comprising the step of performing an isothermal amplification reaction on a sample suspected of containing human parvovirus to generate the amplified human parvovirus nucleic acid.

20 . The method of claim 19 , wherein the isothermal amplification reaction is a transcription-mediated amplification reaction.

Assignments (2)
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: CARRICK, JAMES M
To: GEN-PROBE INCORPORATED
Reel/Frame 055338/0568 →